全文获取类型
收费全文 | 302037篇 |
免费 | 18110篇 |
国内免费 | 424篇 |
专业分类
耳鼻咽喉 | 4307篇 |
儿科学 | 10426篇 |
妇产科学 | 10365篇 |
基础医学 | 46012篇 |
口腔科学 | 7616篇 |
临床医学 | 24780篇 |
内科学 | 57426篇 |
皮肤病学 | 6373篇 |
神经病学 | 21544篇 |
特种医学 | 11824篇 |
外国民族医学 | 43篇 |
外科学 | 47408篇 |
综合类 | 7804篇 |
现状与发展 | 1篇 |
一般理论 | 162篇 |
预防医学 | 20349篇 |
眼科学 | 6982篇 |
药学 | 21394篇 |
中国医学 | 794篇 |
肿瘤学 | 14961篇 |
出版年
2019年 | 2360篇 |
2018年 | 3722篇 |
2017年 | 2763篇 |
2016年 | 3219篇 |
2015年 | 3642篇 |
2014年 | 4749篇 |
2013年 | 7461篇 |
2012年 | 9359篇 |
2011年 | 9754篇 |
2010年 | 6322篇 |
2009年 | 5735篇 |
2008年 | 8984篇 |
2007年 | 9777篇 |
2006年 | 9641篇 |
2005年 | 9225篇 |
2004年 | 8908篇 |
2003年 | 8398篇 |
2002年 | 7953篇 |
2001年 | 13521篇 |
2000年 | 13805篇 |
1999年 | 11579篇 |
1998年 | 3086篇 |
1997年 | 2834篇 |
1996年 | 2684篇 |
1995年 | 2602篇 |
1994年 | 2401篇 |
1992年 | 8448篇 |
1991年 | 8600篇 |
1990年 | 8405篇 |
1989年 | 8218篇 |
1988年 | 7428篇 |
1987年 | 7183篇 |
1986年 | 6846篇 |
1985年 | 6629篇 |
1984年 | 4844篇 |
1983年 | 4214篇 |
1982年 | 2523篇 |
1979年 | 4490篇 |
1978年 | 3281篇 |
1977年 | 2775篇 |
1976年 | 2534篇 |
1975年 | 2866篇 |
1974年 | 3389篇 |
1973年 | 3411篇 |
1972年 | 3143篇 |
1971年 | 2973篇 |
1970年 | 2856篇 |
1969年 | 2597篇 |
1968年 | 2557篇 |
1967年 | 2385篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
22.
23.
24.
25.
26.
27.
Anders Elm Pedersen Esben Gjerløff Wedebye Schmidt Jesper Freddie Sørensen Carsten Faber Boye Schnack Nielsen Kim Holmstrøm Silje Haukali Omland Peter Tougaard Søren Skov Bo Bang 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2015,123(7):547-555
TL1A is a TNF‐like cytokine which has been shown to co‐stimulate TH1 and TH17 responses during chronic inflammation. The expression of this novel cytokine has been investigated in inflammatory disorders like rheumatoid arthritis and inflammatory bowel disease, but little is known about expression and induction in psoriasis. Indeed, the pathogenesis in psoriasis is still not fully understood and it is speculated that cytokines other than TNF‐α are important in subsets of patients. Also, for patients with severe disease that are treated with systemic anti‐TNF‐α blockade, novel candidates to be used as disease and response biomarkers are of high interest. Here, we demonstrate TL1A expression in biopsies from psoriatic lesions. Also, we investigated spontaneous and induced TL1A secretion from PBMCs and blood levels from a cohort of psoriasis patients. Here, increased spontaneous secretion from PBMCs was observed as compared to healthy controls and a small subset of patients had highly elevated TL1A in the blood. Interestingly, activation of PBMCs with various cytokines showed a decreased sensitivity for TL1A activation in psoriasis patients compared to healthy controls.TL1A levels in blood and biopsies could not be correlated with disease activity with this patient cohort. Thus, additional large‐scale studies are warranted to investigate TL1A as a biomarker. 相似文献
28.
Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers
下载免费PDF全文
![点击此处可从《Clinical endocrinology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
29.